Incretin Therapies

Chicago, IL—Targeted therapies and immune-focused agents with novel mechanisms of action yielded impressive outcomes in the early- and late-phase studies that were reported at ASCO 2013.

In a recent head-to-head comparison, glycemic control was better with the glucagon-like peptide-1 (GLP-1) exenatide twice daily than with the sulfonylurea glimepiride once daily in patients with type 2 diabetes who are inadequately controlled with metformin, said Guntram Schernthaner, MD, Head of the Department of Medicine, Rudolfstiftung Hospital, Vienna, Austria, at the 2012 ADA annual meeting. Dr Schernthaner reported the results of the European Exenatide trial known as EUREXA, which was simultaneously published in the Lancet (Gallwitz B, et al. Lancet.

Controlling hypoglycemia is of great concern in this population, because of potential accidents or falls. In addition, elderly patients are at increased risk for adverse events associated with drug therapy; therefore, treatment must be chosen carefully, pointed out Barry Goldstein, MD, PhD, Vice President of Diabetes and Endocrinology Clinical Development, Merck & Co, who presented the results at the 2012 ADA annual meeting.

The contribution of incretin impairment to type 2 diabetes is the focus of ongoing research, and many questions remain to be answered. Preliminary data from several ongoing studies have provided insights into the role of glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase (DPP)-4 in relation to the role of the incretin system in type 2 diabetes.

In a recent head-to-head comparison, glycemic control was better with the glucagon-like peptide-1 (GLP-1) exenatide twice daily than with the sulfonylurea glimepiride once daily in patients with type 2 diabetes who are inadequately controlled with metformin, said Guntram Schernthaner, MD, Head of the Department of Medicine, Rudolfstiftung Hospital, Vienna, Austria, at the 2012 ADA annual meeting. Dr Schernthaner reported the results of the European Exenatide trial known as EUREXA, which was simultaneously published in the Lancet (Gallwitz B, et al. Lancet.

Controlling hypoglycemia is of great concern in this population, because of potential accidents or falls. In addition, elderly patients are at increased risk for adverse events associated with drug therapy; therefore, treatment must be chosen carefully, pointed out Barry Goldstein, MD, PhD, Vice President of Diabetes and Endocrinology Clinical Development, Merck & Co, who presented the results at the 2012 ADA annual meeting.

The contribution of incretin impairment to type 2 diabetes is the focus of ongoing research, and many questions remain to be answered. Preliminary data from several ongoing studies have provided insights into the role of glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase (DPP)-4 in relation to the role of the incretin system in type 2 diabetes.


Results 1 - 7 of 7
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME